Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 10/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | GLB1 | P16278 | 2/20 | 0.45 |
| ▸ | PYGL | P06737 | 1/20 | 0.45 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.45 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL956100 | 1.00 | GBA1 (0.45) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL21408911 | 1.00 | GBA1 (0.45) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL21408888 | 1.00 | GBA1 (0.45) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL14754996 | 0.83 | GBA1 (0.32) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL4755135 | 0.83 | GBA1 (0.35) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL12536231 | 0.83 | GBA1 (0.35) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL5868689 | 0.81 | GBA1 (0.32) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL4685744 | 0.74 | FUCA1 (0.34) | FUCA1 | |
| SCHEMBL14891421 | 0.73 | — | — | |
| SCHEMBL21195896 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| CN-117186108-A | Bruton's tyrosine kinase degradation agent | 诺华股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-111936501-B | Bruton's tyrosine kinase degradation agent | 诺华股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-11541056-B2 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives | NOVARTIS AG (CH) | 2023-01-03 | — | — | US | disclosed |
| US-20210251996-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | NOVARTIS AG (CH) | 2021-08-19 | — | — | US | disclosed |
| EP-3774808-A1 | 3-HYDROXY-N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)PYRROLIDINE-1-CARBOXAMIDE DERIVATIVES | Novartis AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| CN-111936501-A | 3-hydroxy-N- (3- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) phenyl) pyrrolidine-1-carboxamide derivatives | 诺华股份有限公司 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019186358-A1 | 3-HYDROXY-N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)PYRROLIDINE-1-CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2019-10-03 | — | — | WO | disclosed |
| EP-2454263-B1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | ALBERT EINSTEIN COLLEGE MEDICINE INC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9957272-B2 | 3-hydroxypyrrolidine inhibitors of 5′-methylthioadenosine phosphorylase and nucleosidase | VICTORIA LINK LIMITED (NZ) | 2018-05-01 | — | — | US | disclosed |
| US-20170166573-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | VICTORIA LINK LIMITED (NZ) | 2017-06-15 | — | — | US | disclosed |
| US-9493465-B2 | 3-hydroxypyrrolidine inhibitors of 5′-methylthioadenosine phosphorylase and nucleosidase | VICTORIA LINK LIMITED (NZ) | 2016-11-15 | — | — | US | disclosed |
| US-20120157479-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-06-21 | — | — | US | disclosed |
| EP-2454263-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | The Albert Einstein College Of Medicine Of Yeshiva University (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011008110-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | ALBERT EINSTEIN COLLEGE OF YESHIVA UNIVERSITY (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541056-B2 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives | PAH, PKD1, REN | GBA1 336/4885GAA 244/4885GLB1 3984/4885 |
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | PAH, PKD1, REN | GBA1 336/4885GAA 244/4885GLB1 3984/4885 |
| US-20210251996-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | PAH, PKD1, REN | GBA1 336/4885GAA 244/4885GLB1 3984/4885 |
| US-20120157479-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | TYMP, MTAP, PNP | GBA1 318/4885GAA 137/4885GLB1 919/4885 |
| US-20170166573-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | TYMP, MTAP, PNP | GBA1 268/4885GAA 143/4885GLB1 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.